Sequencing.com, a biotech company pioneering whole genome sequencing and personalized health insights, has announced a strategic partnership with PGxAI, a leader in AI-powered pharmacogenomics. The collaboration aims to advance affordable, precision-driven healthcare by integrating comprehensive pharmacogenomic analysis into Sequencing.com’s platform, enabling individuals to make safer, more effective medication decisions based on their unique genetic profiles. As part of the initiative, PGxAI will launch a suite of pharmacogenomic reports on Sequencing.com, providing users with detailed, actionable insights into how their genetics may affect their response to medications. These reports cover more than 730 drugs and 40 clinically relevant genes—offering up to five times the coverage of many competing solutions. The goal is to reduce adverse drug reactions, a major contributor to healthcare costs and patient harm, which currently account for over $150 billion in annual expenses in the United States. “Pharmacogenomics has the potential to reduce adverse drug events by up to 30%,” said Allan Gobbs, Executive Chairman and Co-Founder of PGxAI. “By making this data accessible and actionable, we’re not only improving patient safety but also driving down unnecessary healthcare spending.” Dr. Brandon Colby, Founder and CEO of Sequencing.com, highlighted the growing demand for personalized medicine: “As interest in pharmacogenomics expands, PGxAI’s scientifically rigorous, expansive database brings unmatched value to our users. This partnership accelerates the shift toward proactive, precision health.” Dr. Mike Zack, CEO and Co-Founder of PGxAI and a pharmacogenomics expert from UCSF, emphasized the widespread relevance of genetic variation: “More than 99% of people carry at least one clinically significant drug-gene variant. Harnessing this information allows for smarter, safer prescribing—turning precision medicine from a promise into a reality today.” The new reports are designed for seamless integration with major consumer genetic testing platforms. Users can easily upload their genomic data to receive personalized medication guidance aligned with FDA recommendations and standards set by leading pharmacogenomics consortia. The solution also presents a valuable revenue opportunity for clinical laboratories and genomic service providers, as the reports are plug-and-play and compatible with existing workflows. PGxAI’s platform leverages proprietary AI algorithms and real-world data to analyze drug-gene interactions, optimize dosing, and predict potential side effects. The company, based in Palo Alto and launched in 2023, is backed by ATEM Capital and in strategic partnership with InterSystems. Its advisory board includes prominent figures such as Dr. Russ Altman from Stanford University and executives from Thermo Fisher, GE Healthcare, and Tempus AI. For more information about the partnership and to access the new pharmacogenomic reports, visit www.sequencing.com/marketplace/medications-pgx-complete-dna-guide. Sequencing.com, founded in 2017 by Dr. Brandon Colby, is headquartered in Los Angeles and offers the world’s most comprehensive whole genome sequencing platform. Unlike standard DNA tests that analyze less than 0.1% of the genome, Sequencing.com provides access to 100% of an individual’s genetic data. The company’s team includes medical doctors, geneticists, bioinformatics experts, and software developers who help users interpret their data for conditions ranging from cancer risk and cardiovascular health to autoimmune disorders and rare diseases. The platform is committed to privacy and empowers users to collaborate with healthcare providers and genetic counselors. PGxAI is at the forefront of transforming pharmacogenomics through innovation, data science, and AI. By making personalized drug recommendations accessible and scalable, the company is helping build a future where treatment is not one-size-fits-all, but precisely tailored to the individual.